|
Originally published In Press as doi:10.1074/jbc.C000275200 on May 22, 2000
J. Biol. Chem., Vol. 275, Issue 29, 21805-21808, July 21, 2000
ACCELERATED PUBLICATION
Bile Acid Induction of Cytokine Expression by Macrophages
Correlates with Repression of Hepatic Cholesterol 7 -Hydroxylase*
Jon H.
Miyake ,
Shui-Long
Wang , and
Roger A.
Davis§
From the Mammalian Cell and Molecular Biology Laboratory, San
Diego State University, San Diego, California 92182-4614
Received for publication, April 21, 2000, and in revised form, May 17, 2000
 |
ABSTRACT |
In the studies reported herein, we
show that two complementary experimental models: inbred strains of mice
(i.e. C57BL/6 and C3H/HeJ), and a differentiated line of
rat hepatoma cells (i.e. L35 cells), require the activation
of cytokines by monocyte/macrophages to display bile acid negative
feedback repression of cholesterol 7 -hydroxylase (CYP7A1). Feeding a
bile acid-containing atherogenic diet for 3 weeks to C57BL/6 mice led
to a 70% reduction in the expression of hepatic CYP7A1 mRNA,
whereas no reduction was observed in C3H/HeJ mice. The strain-specific
response to repression of CYP7A1 paralleled the activation of hepatic
cytokine expression. Studies using cultured THP-1 monocyte/macrophages
showed that the hydrophobic bile acid chenodeoxycholate, a well
established potent repressor of CYP7A1, induced the expression of
mRNAs encoding interleukin 1 (IL-1) and tumor necrosis factor (TNF ). In contrast, the hydrophilic bile acid ursodeoxycholate,
which does not repress CYP7A1, did not induce cytokine mRNA
expression by THP-1 cells. Chenodeoxycholate activation of cytokines by
THP-1 cells was blocked by the peroxisome proliferator-activated
receptor agonist rosiglitazone. The expression of cytokines
(e.g. IL-1 and TNF ) by THP-1 cells paralleled with the
ability of these cells to produce conditioned medium that when added to
rat L35 hepatoma cells, repressed CYP7A1. Moreover, rosiglitazone,
which blocks cytokine activation by macrophages, also blocked the
repression of CYP7A1 normally exhibited by C57BL/6 mice fed the bile
acid-containing atherogenic diet. The combined data indicate that the
activation of cytokines may mediate CYP7A1 repression caused by feeding
mice an atherogenic diet containing bile acids.
 |
INTRODUCTION |
Bile acids, the major metabolites produced from cholesterol, are
amphipathic steroid detergents necessary for the digestion and
absorption of fat soluble nutrients from the intestine (1-3). The
conversion of cholesterol to bile acids is regulated by the expression
of cholesterol 7 -hydroxylase
(CYP7A1),1 a cytochrome P450
enzyme unique to the liver parenchymal cell (4-6). Bile acid synthesis
exhibits negative feedback regulation (7, 8) by decreasing the
enzymatic activity of CYP7A1 (9). It is generally accepted that bile
acids can inhibit the transcription of the CYP7A1 gene (1-3).
Many different experimental models have been used to examine bile acid
negative feedback regulation of CYP7A1 and some have yielded
conflicting results. Bile acid negative feedback repression of CYP7A1
has been experimentally demonstrated by infusing bile acids into the
intestine of bile fistulae rats (10) and hamsters (11). The ability of
different bile acids to repress CYP7A1 expression correlates with the
hydrophobic index of the infused bile acid; CDCA is a potent repressor,
whereas UDCA is not (12). The finding that infusing taurocholate into
the portal vein of bile fistulae mice was unable to repress CYP7A1 led
to the conclusion that a factor produced within the enterohepatic
circulation may be required to repress CYP7A1 (10).
Bile acid repression of CYP7A1 has been demonstrated using primary
cultured rat hepatocytes (13) and human hepatoma HepG2 cells (14-16).
Data from these cultured cell studies suggest that multiple mechanisms
exist in regard to bile acid repression of CYP7A1 expression. These
mechanisms include: "bile acid response" elements (BARE) (17),
activation of protein kinase C (18), and activation of the farnesoid X
receptor (FXR) (16, 19).
L35 is a stable line of rat hepatoma cells that have been used for
studies examining the expression of CYP7A1 (20-22). L35 cells express
CYP7A1 at levels equal to that of rat liver, which is 10-fold greater
than the levels expressed by either HepG2 cells or primary rat
hepatocytes (20). Moreover, with the one notable exception of
resistance to repression by bile acids, the expression of CYP7A1 by L35
cells responded normally to essentially all the effectors established
to alter CYP7A1 expression in vivo (20-22). The inability
of bile acids to repress CYP7A1 expression by L35 cells led to the
proposal that they are missing factors necessary to mediate this
repression (21).
In the studies reported herein, we show that these factors are
cytokines produced by macrophages.
 |
MATERIALS AND METHODS |
Mouse Studies--
Female C3H/HeJ and C57BL/6 mice 10-12 weeks
old were obtained from Jackson Laboratory, Bar Harbor, ME. The mice
were housed in a room with a normal light cycle (lights on from 6 a.m. to 6 p.m.) were fed either normal Purina breeder chow or
ground Purina breeder chow supplemented with 20% olive oil, 2%
cholesterol, and 0.5% taurocholic acid (bile acid-containing
atherogenic diet) and water ad libitum. Mice were maintained
on the above diets for 3 weeks.
In the experiments examining the effect of rosiglitazone on CYP7A1
expression, C57BL/6 mice fed the chow diet and the bile acid-containing
atherogenic diet were divided into two groups. Half the mice in each
diet group were given either vehicle (0.25% Tween 80, 1%
carboxymethylcellulose) alone or vehicle containing 1 mg/ml of
rosiglitazone daily by oral gavage. Mice were sacrificed at 9 a.m., and blood was obtained for subsequent analysis. Poly(A) RNA was
isolated from mouse livers, as described previously (23, 24).
Hepatic cytokine mRNAs were quantitated using RNase protection
assays. In vitro transcribed
[ 32P]UTP-labeled antisense cytokine probes were
generated using cytokine multiprobe template kits: mouse mCK-2 (catalog
number 45002P) and mouse mCK-3 (catalog number 45003P; PharMingen
International) and a MAXIscript in vitro transcription kit
(catalog number 1314) using T7 RNA polymerase per the manufacturer's
instructions. The content of human cytokines mRNAs was also
quantitated by RNase protection assays except human template kits were
used (human hCK-2, catalog number 45032P and human hCK-3, catalog
number 45033P; PharMingen International).
Cultured Cell Studies--
Rat L35 cells were cultured in DMEM
(21, 22). THP-1 cells were cultured in RPMI medium 1640 plus 10% FBS
containing: 0.1% BSA, 0.1% BSA with and without CDCA (100 µM), 0.1% BSA containing UDCA (100 µM) and
rosiglitazone (as indicated in Fig. 2). Cells were harvested, and
poly(A) RNA was isolated, as described previously (21, 22). Statistical
significance was determined by Student's t test using
double-tailed p values.
 |
RESULTS AND DISCUSSION |
When fed the bile acid-containing atherogenic diet, C57BL/6 mice
display repression of CYP7A1, whereas C3H/HeJ mice do not (23-25).
Quantitative trait loci analysis of C3H/HeJ and C57BL/6 mice shows that
marked phenotypic differences exist in regard to displaying
inflammation in response to consuming the bile acid-containing atherogenic diet (26, 27). C3H/HeJ display essentially a complete resistance to hepatic inflammation, whereas C57BL/6 display a remarkable susceptibility (26, 27). We examined if strain-specific differences in cytokine activation might be the basis for the strain-specific differences in CYP7A1 repression. On the normal chow
diet, the expression of CYP7A1 mRNA expression was similar in
C57BL/6 and C3H/HeJ mice (Fig. 1,
A and B). In contrast, the bile acid-containing
atherogenic diet caused marked differences in the expression of CYP7A1
by the two strains of mice. While C3H/HeJ mice displayed no significant
change in CYP7A1 expression, C57BL/6 mice showed a marked 70%
decrease, p < 0.01 (Fig. 1, A and
B).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 1.
In inbred strains of mice fed diets with and
without bile acids, CYP7A1 mRNA expression (A and
B) varies inversely with the relative expression of
hepatic cytokine mRNAs (C), suggesting a model
(D) in which cytokines produced by hepatic macrophages
mediate bile acid repression of CYP7A1. Female C57BL/6J and
C3H/HeJ mice were housed in a room with a normal light cycle (lights on
from 6 a.m. to 6 p.m.) and fed water ad libitum
with either a chow diet or a bile acid-containing atherogenic diet.
After 3 weeks, mice were sacrificed at 9 a.m. A, livers
were extracted for RNA, and poly(A) RNA was isolated, blotted onto
nitrocellulose, and probed with 32P-labeled cDNA
encoding rat CYP7A1 and GAPDH as a loading control. B, the
abundance of CYP7A1 mRNA relative to GAPDH is shown as the
mean ± S.D. of three individual mice in each group. The
asterisk denotes a significant difference between the
C57BL/6 mice fed the chow diet and C57BL/6 mice fed the bile
acid-containing atherogenic diet (p < 0.01).
C, the hepatic content of the indicated cytokine mRNAs
was determined using an RNase protection assay. L32 and GAPDH are RNA
loading controls. D, based on the findings showing that
dietary bile acids alter the expression of CYP7A1 in a manner that is
inversely related to their activation of hepatic cytokines, we propose
the model schematically represented in this figure. This model predicts
that bile acids returning to the liver via the portal blood interact
with hepatic macrophages (Kupffer cells) as they traverse the
sinusoidal surface to enter the parenchymal cell. The type of bile acid
and its concentration in portal blood determines whether cytokine
expression by macrophages is increased. The ability of bile acids to
induce the expression of regulatory cytokines subsequently determines
whether CYP7A1 will be repressed by this mechanism.
|
|
The individual strains also displayed distinct differences in the
response of hepatic cytokine expression to the bile acid-containing atherogenic diet (Fig. 1C). In C57BL/6 mice, the bile
acid-containing atherogenic diet increased the hepatic expression of
mRNAs encoding IL-1 (7-fold, p < 0.01), IL-1
(4-fold, p < 0.01), TNF (3-fold, p < 0.01), IFN (6-fold, p < 0.01), and TGF- 1
(7-fold, p < 0.01) (Fig. 1C). In marked
contrast, the expression of hepatic cytokines by C3H/HeJ mice was
unaffected by the bile acid-containing atherogenic diet (Fig.
1C). The concordance between the ability of the bile acid-containing atherogenic diet to induce the expression of mRNAs encoding cytokines while repressing CYP7A1 mRNA expression
suggested the possibility that cytokines might mediate the repression
of CYP7A1 caused by the bile acid-containing atherogenic diet. Indeed, recent studies have shown that administering lipopolysaccharide as well
as the cytokines TNF or IL-1 to hamsters resulted in a marked
suppression of CYP7A1 (28).
Based on these combined findings, we formulated the following
experimentally testable model (Fig. 1D). Following their
active absorption in the distal intestine, bile acids return to the
liver via the portal vein entering the hepatic parenchymal cell by
crossing through the sinusoids. As bile acids move across the
sinusoids, they may interact with resident macrophages (i.e.
Kupffer cells) which reside along the sinusoidal surface. At sufficient
concentration, bile acids may cause the activation of cytokines by
Kupffer cells. These regulatory cytokines may subsequently act on
hepatic parenchymal cells, leading to the repression of CYP7A1
(28).
We attempted to reconstruct this model using the cultured rat hepatoma
cell line (L35 cells) and human monocyte/macrophages (THP-1 cells). To
approximate the intercellular relationships that may exist between
hepatic macrophages and parenchymal cells (Fig. 1D), THP-1
cells were exposed to bile acids and the effects of the conditioned
medium was examined on the expression of CYP7A1 by L35 cells. CYP7A1
expression by L35 cells was unaffected by changing the culture medium
to serum-free DMEM, without dexamethasone but containing either 0.1%
BSA or 0.1% BSA containing the hydrophobic bile acid CDCA (100 µM) or conditioned medium obtained from THP-1 cells (Fig.
2A). However, changing the
cultured medium to serum-free DMEM, without dexamethasone but
containing conditioned medium obtained from THP-1 cells exposed to
CDCA, repressed CYP7A1 expression by >70% (Fig. 2A). These
data indicate that: 1) CDCA requires THP-1 cells to repress CYP7A1
expression by L35 cells, and 2) CDCA caused THP-1 cells to secrete a
factor that repressed CYP7A1.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 2.
The expression of cytokine mRNAs by THP-1
cells correlates with the ability of conditioned medium to repress
CYP7A1 mRNA expression by rat hepatoma L35 cells.
A, CDCA requires THP-1 cells to repress CYP7A1 expression by
L35 cells. Rat hepatoma L35 cells were cultured in serum-free medium
containing 100 µM dexamethasone for 24 h. The
cultured medium was then changed to serum-free DMEM medium containing
the following additions: 0.1% BSA (Control), 0.1% BSA
containing 100 µM CDCA (CDCA), the addition of
50% by volume of medium from THP-1 cells, which was incubated for
48 h with either 0.1% BSA (THP-1) or 0.1% BSA
containing 100 µM CDCA (THP-1 + CDCA). After
24 h, cells were harvested, and poly(A) RNA was isolated, blotted
onto nitrocellulose, and probed sequentially with
32P-labeled cDNAs encoding rat CYP7A1 and -actin.
B, CDCA, but not UDCA, induces the expression of cytokine
mRNA by THP-1 cells via a process that is blocked by the PPAR
agonist rosiglitazone. THP-1 cells were cultured in RPMI 1640 medium
containing 10% FBS and then treated with either 0.1% BSA (lanes
1 and 5), 0.1% BSA containing 100 µM
UDCA (lanes 2 and 6), 0.1% BSA containing 100 µM CDCA (lanes 3 and 7), or 0.1%
BSA containing 100 µM CDCA and 500 nM
rosiglitazone (BRL) (lanes 4 and 8).
RNA was isolated and subjected to RNase protection assay for the
indicated cytokines. L32 and GAPDH are RNA loading controls.
C, the PPAR agonist rosiglitazone blocks the CDCA-induced
repression of CYP7A1 in L35 cells by conditioned medium from THP-1
cells. Rat hepatoma L35 cells were cultured in serum-free medium
containing 100 µM dexamethasone for 24 h. The
cultured medium was then changed to serum-free DMEM containing the
following additions (50% by volume): conditioned medium obtained from
THP-1 cells incubated with 0.1% BSA (THP-1) or 0.1% BSA
containing 100 µM CDCA or 0.1% BSA containing 100 µM CDCA and 500 nM rosiglitazone
(BRL). After 24 h, cells were harvested, and the
relative level of CYP7A mRNA to -actin mRNA was quantitated.
Each value represents the mean of duplicate plates of cells.
D, TNF- represses the expression of CYP7A1 mRNA by
L35 cells. L35 cells cultured in serum-free DMEM medium containing 100 µM dexamethasone were treated with the indicated
concentrations of human TNF- for 24 h. Each value represents
the level of CYP7A mRNA to -actin mRNA as the mean ± S.D of three replicate plates of cells.
|
|
To further examine the validity of our hypothesis (Fig. 1D),
we determined if CDCA altered the expression of cytokine mRNAs by
THP-1 cells (Fig. 2B). CDCA caused THP-1 cells to markedly increase (~10-fold) their expression of TNF , TGF- 1, and IL-1 mRNAs. In contrast, the hydrophilic bile acid, UDCA, which does not
repress CYP7A1 (12), did not induce the expression of the regulatory
cytokines TNF , TGF- 1, and IL-1 (Fig. 2B).
According to our hypothesis (Fig. 1D) cytokines mediate the
repression of CYP7A1 caused by dietary bile acids. Thus, our model predicts that blocking the activation of cytokines by bile acids should
block the repression of CYP7A1. PPAR agonism inhibits the production
of inflammatory cytokines by monocyte/macrophages (29). Therefore, if
our model is valid, the PPAR agonist rosiglitazone should prevent
repression of CYP7A1. Treating THP-1 cells with rosiglitazone
completely blocked the ability of CDCA to induce the expression of
cytokine mRNAs (Fig. 2B). Rosiglitazone also blocked the
ability of THP-1 cells exposed to CDCA to produce conditioned medium
that could repress CYP7A1 expression by L35 cells (Fig. 2C).
The additional finding that TNF caused a dose-dependent decrease in the expression of CYP7A1 mRNA by L35 cells (Fig.
2D) further indicates that cytokines produced by THP-1 cells
in response to CDCA are responsible for repression of CYP7A1.
Further analysis showed that L35 cells did not express detectable
levels of mRNAs encoding the regulatory cytokines TNF , TGF- 1,
or IL-1 (data not shown). Treatment of L35 cells with culture medium
containing CDCA or rosiglitazone did not induce the expression of these
cytokines to detectable levels (data not shown). In marked contrast to
L35 cells, HepG2 cells display the ability to express most inflammatory
cytokines (30, 31). The inability of L35 cells to express TNF ,
TGF- 1, or IL-1 may explain their requirement for THP-1 cells to
observe a CDCA repression of CYP7A1 (Fig. 2, A and
B).
Our model also predicts that blocking the activation of cytokines by
dietary bile acids in C57BL/6 mice should result in the C3H/HeJ
phenotype (i.e. resistance to both the activation of hepatic cytokines and the repression of CYP7A1; Fig. 1). We, therefore, determined if treating C57BL/6 mice with rosiglitazone would prevent repression of CYP7A1 by the bile acid-containing atherogenic diet. Rosiglitazone treatment of chow-fed C57BL/6 mice did not alter the
expression of CYP7A1. However, in C57BL/6 mice fed the bile acid-containing atherogenic diet, administration of rosiglitazone blocked the repression of CYP7A1 (Fig.
3). Our combined data suggest that the
ability to induce the expression of hepatic cytokines in response to
the bile acid-containing atherogenic diet is responsible for the
divergent phenotypic response exhibited by C57BL/6 and C3H/HeJ mice.
Thus, C57BL/6 mice display an induction of hepatic cytokine expression
(Fig. 1B) and a repression of CYP7A1 (Fig. 1A),
whereas C3H/HeJ neither display an induction of hepatic cytokines nor a
repression of CYP7A1. In essence, rosiglitazone treatment caused
C57BL/6 mice to display the C3H/HeJ phenotype in regard to resistance
to repression of CYP7A1 by dietary bile acids.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
The PPAR agonist
rosiglitazone blocks the repression of CYP7A1 mRNA caused by
feeding C57BL/6 mice the bile acid-containing atherogenic diet.
Female C57BL/6 mice (n = 24) were fed either chow or
the bile acid-containing atherogenic diet. Half the mice in each
feeding group were given either vehicle (0.25% Tween 80, 1%
carboxymethylcellulose) alone or vehicle containing 1 mg/ml of
rosiglitazone daily by oral gavage. After 3 weeks, mice were
sacrificed, and the relative content of rat CYP7A1 mRNA compared
with GAPDH was determined. Each value represents the mean ± S.D
of six separate mice. The asterisk denotes a significant
difference between the values for the rosiglitazone-treated chow-fed
mice and the rosiglitazone mice fed the bile acid-containing
atherogenic diet, p < 0.01.
|
|
Our findings do not exclude other mechanisms, independent of cytokines,
acting to repress CYP7A1 in response to bile acids. In experimental
models other than inbred mice and L35 cells, bile acid repression of
CYP7A1 has been shown to involve BARE (17), activation of protein
kinase C (18), and activation of FXR (16, 19). The structure of the
bile acid influences its ability to repress CYP7A1 (12) and activate
FXR (16, 19, 32). Our additional findings showing that while
unconjugated CDCA activated THP1 cells to produce cytokine repressors
of CYP7A1 (Fig. 2), its taurine and glycine conjugates were without
effect (data not shown) are consistent with the distinct physiochemical
and physiological properties of unconjugated and conjugated bile acids.
Conjugated bile acids require cell type-specific bile acid transporters
to be efficiently taken up by cells in the ileum and liver (33). In
contrast, unconjugated bile acids can enter cells lacking bile acid
transporters via diffusion (33). Our combined results suggest that the
unconjugated, hydrophobic bile acid CDCA entering the enterohepatic
circulation via intestinal absorption may initiate CYP7A1 repression
via the activation of regulatory cytokines by resident macrophages.
Therefore, it is likely that the composition and concentration of the
bile acid pool within the enterohepatic circulation determines which of
several possible mechanisms will be invoked in regard to regulating the
expression of CYP7A1.
 |
ACKNOWLEDGEMENTS |
William Strauss is acknowledged for his help
with the Northern blots and cell culture. We thank Simon Hui, Alan
Attie, Alan Hoffmann, Chris Glass, and Peter Edwards for their helpful suggestions.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants HL57974 and HL57974.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Each author contributed equally to this work.
§
To whom correspondence should be addressed: Mammalian Cell and
Molecular Biology Laboratory, Life Sciences Bldg. LS307, 5500 Campanile
Dr., San Diego State University, San Diego, CA 92182-4614. Tel.:
619-594-7936; Fax: 619-594-7937; E-mail: rdavis@sunstroke. sdsu.edu.
Published, JBC Papers in Press, May 22, 2000, DOI 10.1074/jbc.C000275200
 |
ABBREVIATIONS |
The abbreviations used are:
CYP7A1, cholesterol
7 -hydroxylase;
BSA, bovine serum albumin;
CDCA, chenodeoxycholic
acid;
UDCA, ursodeoxycholic acid;
DMEM, Dulbecco's modified Eagle's
medium;
FBS, fetal bovine serum;
FXR, farnesoid X receptor;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
HDL, high density
lipoprotein;
IL-1, interleukin 1;
IFN- , interferon gamma;
PPAR , peroxisome proliferator-activated receptor ;
TGF- , transforming
growth factor ;
TNF- , tumor necrosis factor ;
BARE, bile acid
response element.
 |
REFERENCES |
| 1.
|
Russell, D. W.,
and Setchell, K. D.
(1992)
Biochemistry
31,
4737-4749
|
| 2.
|
Vlahcevic, Z. R.,
Pandak, W. M.,
Heuman, D. M.,
and Hylemon, P. B.
(1992)
in
Seminars in Liver Disease
(Rothschild, M. A., ed), Vol. 12
, pp. 403-419, Thieme Medical Publishers, New York
|
| 3.
|
Edwards, P. A.,
and Davis, R. A.
(1996)
in
New Comprehensive Biochemistry
(Vance, D. E.
, and Vance, J., eds), 1st Ed., Vol. 31
, pp. 341-362, Elsevier Science Publishers B. V., Amsterdam
|
| 4.
|
Noshiro, M.,
and Okuda, K.
(1990)
FEBS Lett.
268,
137-140
|
| 5.
|
Jelinek, D. F.,
Andersson, S.,
Slaughter, C. A.,
and Russell, D. W.
(1990)
J. Biol. Chem.
265,
8190-8197
|
| 6.
|
Li, Y. C.,
Wang, D. P.,
and Chiang, J. Y. L.
(1990)
J. Biol. Chem.
265,
12012-12019
|
| 7.
|
Bergstrom, S.,
and Danielsson, H.
(1958)
Acta Physiol. Scand.
43,
1-7
|
| 8.
|
Shefer, S.,
Hauser, S.,
Bekersky, I.,
and Mosbach, E. H.
(1969)
J. Lipid Res.
10,
646-655
|
| 9.
|
Shefer, S.,
Hauser, S.,
Bekersky, I.,
and Mosbach, E. H.
(1970)
J. Lipid Res.
11,
404-411
|
| 10.
|
Pandak, W. M.,
Li, Y. C.,
Chiang, J. Y.,
Studer, E. J.,
Gurley, E. C.,
Heuman, D. M.,
Vlahcevic, Z. R.,
and Hylemon, P. B.
(1991)
J. Biol. Chem.
266,
3416-3421
|
| 11.
|
Spady, D. K.,
Cuthbert, J. A.,
Willard, M. N.,
and Meidell, R. S.
(1996)
J. Biol. Chem.
271,
18623-18631
|
| 12.
|
Heuman, D. M.,
Hylemon, P. B.,
and Vlahcevic, Z. R.
(1989)
J. Lipid Res.
30,
1161-1171
|
| 13.
|
Stravitz, R. T.,
Hylemon, P. B.,
Heuman, D. M.,
Hagey, L. R.,
Schteingart, C. D.,
Nu, H. T.,
Hofmann, A. F.,
and Vlahcevic, Z. R.
(1993)
J. Biol. Chem.
268,
13987-13993
|
| 14.
|
Crestani, M.,
Karam, W. G.,
and Chiang, J. Y. L.
(1994)
Biochem. Biophys. Res. Commun.
198,
546-553
|
| 15.
|
Taniguchi, T.,
Chen, J.,
and Cooper, A. D.
(1994)
J. Biol. Chem.
269,
10071-10078
|
| 16.
|
Makishima, M.,
Okamoto, A. Y.,
Repa, J. J.,
Tu, H.,
Learned, R. M.,
Luk, A.,
Hull, M. V.,
Lustig, K. D.,
Mangelsdorf, D. J.,
and Shan, B.
(1999)
Science
284,
1362-1365
|
| 17.
|
Crestani, M.,
Sadeghpour, A.,
Stroup, D.,
Galli, G.,
and Chiang, J. Y.
(1998)
J. Lipid Res.
39,
192-200
|
| 18.
|
Stravitz, R. T.,
Vlahcevic, Z. R.,
Gurley, E. C.,
and Hylemon, P. B.
(1995)
J. Lipid Res.
36,
1359-1369
|
| 19.
|
Wang, H.,
Chen, J.,
Hollister, K.,
Sowers, L. C.,
and Forman, B. M.
(1999)
Mol. Cell
3,
543-553
|
| 20.
|
Leighton, J. K.,
Dueland, S.,
Straka, M. S.,
Trawick, J.,
and Davis, R. A.
(1991)
Mol. Cell. Biol.
11,
2049-2056
|
| 21.
|
Trawick, J. D.,
Lewis, K. D.,
Dueland, S.,
Moore, G. L.,
Simon, F. R.,
and Davis, R. A.
(1996)
J. Lipid Res.
37,
24169-24176
|
| 22.
|
Trawick, J. D.,
Wang, S.-L.,
Bell, D.,
and Davis, R. A.
(1997)
J. Biol. Chem.
272,
3099-3102
|
| 23.
|
Dueland, S.,
Drisko, J.,
Graf, L.,
Machleder, D.,
Lusis, A. J.,
and Davis, R. A.
(1993)
J. Lipid Res.
34,
923-931
|
| 24.
|
Dueland, S.,
France, D.,
Wang, S.-L.,
Trawick, J. D.,
and Davis, R. A.
(1997)
J. Lipid Res.
38,
1445-1453
|
| 25.
|
Machleder, D.,
Ivandic, B.,
Welch, C.,
Castellani, L.,
Reue, K.,
and Lusis, A. J.
(1997)
J. Clin. Invest.
99,
1406-1419
|
| 26.
|
Liao, F.,
Andalibi, A.,
deBeer, F. C.,
Fogelman, A. M.,
and Lusis, A. J.
(1993)
J. Clin. Invest.
91,
2572-2579
|
| 27.
|
Liao, F.,
Andalibi, A.,
Qiao, J. H.,
Allayee, H.,
Fogelman, A. M.,
and Lusis, A. J.
(1994)
J. Clin. Invest.
94,
877-884
|
| 28.
|
Feingold, K. R.,
Spady, D. K.,
Pollock, A. S.,
Moser, A. H.,
and Grunfeld, C.
(1996)
J. Lipid Res.
37,
223-228
|
| 29.
|
Jiang, C.,
Ting, A. T.,
and Seed, B.
(1998)
Nature
391,
82-86
|
| 30.
|
Gutierrez, R. M.,
Quiroz, S. C.,
Souza, V.,
Bucio, L.,
Hernandez, E.,
Olivares, I. P.,
Llorente, L.,
Vargas, V. F.,
and Kershenobich, D.
(1999)
Toxicology
134,
197-207
|
| 31.
|
Stonans, I.,
Stonane, E.,
Russwurm, S.,
Deigner, H. P.,
Bohm, K. J.,
Wiederhold, M.,
Jager, L.,
and Reinhart, K.
(1999)
Cytokine
11,
151-156
|
| 32.
|
Parks, D. J.,
Blanchard, S. G.,
Bledsoe, R. K.,
Chandra, G.,
Consler, T. G.,
Kliewer, S. A.,
Stimmel, J. B.,
Willson, T. M.,
Zavacki, A. M.,
Moore, D. D.,
and Lehmann, J. M.
(1999)
Science
284,
1365-1368
|
| 33.
|
Love, M. W.,
and Dawson, P. A.
(1998)
Curr. Opin. Lipidol.
9,
225-229
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. B. Hylemon, H. Zhou, W. M. Pandak, S. Ren, G. Gil, and P. Dent
Bile acids as regulatory molecules
J. Lipid Res.,
August 1, 2009;
50(8):
1509 - 1520.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Zhang, X. Huang, Z. Meng, B. Dong, S. Shiah, D. D. Moore, and W. Huang
Significance and Mechanism of CYP7a1 Gene Regulation during the Acute Phase of Liver Regeneration
Mol. Endocrinol.,
February 1, 2009;
23(2):
137 - 145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Li, H. Ma, and J. Y. L. Chiang
TGF{beta}1, TNF{alpha}, and insulin signaling crosstalk in regulation of the rat cholesterol 7{alpha}-hydroxylase gene expression
J. Lipid Res.,
September 1, 2008;
49(9):
1981 - 1989.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Davis
Resolving the mechanism of bile acid negative-feedback regulation, a Journal of Lipid Research tradition
J. Lipid Res.,
January 1, 2008;
49(1):
2 - 3.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Kim, K. Morimura, Y. Shah, Q. Yang, J. M. Ward, and F. J. Gonzalez
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
Carcinogenesis,
May 1, 2007;
28(5):
940 - 946.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Lickteig, A. L. Slitt, M. C. Arkan, M. Karin, and N. J. Cherrington
Differential Regulation of Hepatic Transporters in the Absence of Tumor Necrosis Factor-{alpha}, Interleukin-1{beta}, Interleukin-6, and Nuclear Factor-{kappa}B in Two Models of Cholestasis
Drug Metab. Dispos.,
March 1, 2007;
35(3):
402 - 409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. P. Ratliff, A. Gutierrez, and R. A. Davis
Transgenic expression of CYP7A1 in LDL receptor-deficient mice blocks diet-induced hypercholesterolemia
J. Lipid Res.,
July 1, 2006;
47(7):
1513 - 1520.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gutierrez, E. P. Ratliff, A. M. Andres, X. Huang, W. L. McKeehan, and R. A. Davis
Bile Acids Decrease Hepatic Paraoxonase 1 Expression and Plasma High-Density Lipoprotein Levels Via FXR-Mediated Signaling of FGFR4
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2006;
26(2):
301 - 306.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Inoue, A.-M. Yu, S. H. Yim, X. Ma, K. W. Krausz, J. Inoue, C. C. Xiang, M. J. Brownstein, G. Eggertsen, I. Bjorkhem, et al.
Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4{alpha}
J. Lipid Res.,
January 1, 2006;
47(1):
215 - 227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Zollner, M. Wagner, P. Fickert, A. Geier, A. Fuchsbichler, D. Silbert, J. Gumhold, K. Zatloukal, A. Kaser, H. Tilg, et al.
Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver
Am J Physiol Gastrointest Liver Physiol,
November 1, 2005;
289(5):
G798 - G805.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Qin, L. A. Borges-Marcucci, M. J. Evans, and D. C. Harnish
Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes
Am J Physiol Gastrointest Liver Physiol,
August 1, 2005;
289(2):
G267 - G273.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Jahan and J. Y. L. Chiang
Cytokine regulation of human sterol 12{alpha}-hydroxylase (CYP8B1) gene
Am J Physiol Gastrointest Liver Physiol,
April 1, 2005;
288(4):
G685 - G695.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Isoda, S. Sawada, M. Ayaori, T. Matsuki, R. Horai, Y. Kagata, K. Miyazaki, M. Kusuhara, M. Okazaki, O. Matsubara, et al.
Deficiency of Interleukin-1 Receptor Antagonist Deteriorates Fatty Liver and Cholesterol Metabolism in Hypercholesterolemic Mice
J. Biol. Chem.,
February 25, 2005;
280(8):
7002 - 7009.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. C-W. Yu, C. David, S. Kadambi, A. Stahl, K.-I. Hirata, T. Ishida, T. Quertermous, A. D. Cooper, and S. Y. Choi
Endothelial lipase is synthesized by hepatic and aorta endothelial cells and its expression is altered in apoE-deficient mice
J. Lipid Res.,
September 1, 2004;
45(9):
1614 - 1623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Freeman, A. Kennedy, J. Wu, S. Bark, A. T. Remaley, S. Santamarina-Fojo, and H. B. Brewer Jr.
The orphan nuclear receptor LRH-1 activates the ABCG5/ABCG8 intergenic promoter
J. Lipid Res.,
July 1, 2004;
45(7):
1197 - 1206.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Riddick, C. Lee, A. Bhathena, Y. E. Timsit, P.-Y. Cheng, E. T. Morgan, R. A. Prough, S. L. Ripp, K. K. M. Miller, A. Jahan, et al.
TRANSCRIPTIONAL SUPPRESSION OF CYTOCHROME P450 GENES BY ENDOGENOUS AND EXOGENOUS CHEMICALS
Drug Metab. Dispos.,
April 1, 2004;
32(4):
367 - 375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gupta, R. Natarajan, S. G. Payne, E. J. Studer, S. Spiegel, P. Dent, and P. B. Hylemon
Deoxycholic Acid Activates the c-Jun N-terminal Kinase Pathway via FAS Receptor Activation in Primary Hepatocytes: ROLE OF ACIDIC SPHINGOMYELINASE-MEDIATED CERAMIDE GENERATION IN FAS RECEPTOR ACTIVATION
J. Biol. Chem.,
February 13, 2004;
279(7):
5821 - 5828.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. J. Kovacs, J. E. Shackelford, K. N. Tape, M. J. Richards, P. L. Faust, S. J. Fliesler, and S. K. Krisans
Disturbed Cholesterol Homeostasis in a Peroxisome-Deficient PEX2 Knockout Mouse Model
Mol. Cell. Biol.,
January 1, 2004;
24(1):
1 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Xu, H. Li, L.-x. Pan, Q. Shang, A. Honda, M. Ananthanarayanan, S. K. Erickson, B. L. Shneider, S. Shefer, J. Bollineni, et al.
FXR-mediated down-regulation of CYP7A1 dominates LXR{alpha} in long-term cholesterol-fed NZW rabbits
J. Lipid Res.,
October 1, 2003;
44(10):
1956 - 1962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Lyons, H. Wittenburg, R. Li, K. A. Walsh, M. R. Leonard, R. Korstanje, G. A. Churchill, M. C. Carey, and B. Paigen
Lith6: a new QTL for cholesterol gallstones from an intercross of CAST/Ei and DBA/2J inbred mouse strains
J. Lipid Res.,
September 1, 2003;
44(9):
1763 - 1771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kang, N. J. Spann, T. Y. Hui, and R. A. Davis
ARP-1/COUP-TF II Determines Hepatoma Phenotype by Acting as Both a Transcriptional Repressor of Microsomal Triglyceride Transfer Protein and an Inducer of CYP7A1
J. Biol. Chem.,
August 15, 2003;
278(33):
30478 - 30486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Lyons, H. Wittenburg, R. Li, K. A. Walsh, M. R. Leonard, G. A. Churchill, M. C. Carey, and B. Paigen
New quantitative trait loci that contribute to cholesterol gallstone formation detected in an intercross of CAST/Ei and 129S1/SvImJ inbred mice
Physiol Genomics,
August 15, 2003;
14(3):
225 - 239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Holt, G. Luo, A. N. Billin, J. Bisi, Y. Y. McNeill, K. F. Kozarsky, M. Donahee, D. Y. Wang, T. A. Mansfield, S. A. Kliewer, et al.
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis
Genes & Dev.,
July 1, 2003;
17(13):
1581 - 1591.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Trauner and J. L. Boyer
Bile Salt Transporters: Molecular Characterization, Function, and Regulation
Physiol Rev,
April 1, 2003;
83(2):
633 - 671.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Y. L. Chiang
Bile Acid Regulation of Hepatic Physiology: III. Bile acids and nuclear receptors
Am J Physiol Gastrointest Liver Physiol,
March 1, 2003;
284(3):
G349 - G356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-C. Gerbod-Giannone, A. del Castillo-Olivares, S. Janciauskiene, G. Gil, and P. B Hylemon
Suppression of Cholesterol 7alpha -Hydroxylase Transcription and Bile Acid Synthesis by an alpha 1-Antitrypsin Peptide via Interaction with alpha 1-Fetoprotein Transcription Factor
J. Biol. Chem.,
November 1, 2002;
277(45):
42973 - 42980.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Hartmann, A. K. Y. Cheung, and M. Piquette-Miller
Inflammatory Cytokines, but Not Bile Acids, Regulate Expression of Murine Hepatic Anion Transporters in Endotoxemia
J. Pharmacol. Exp. Ther.,
October 1, 2002;
303(1):
273 - 281.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Y. L. Chiang
Bile Acid Regulation of Gene Expression: Roles of Nuclear Hormone Receptors
Endocr. Rev.,
August 1, 2002;
23(4):
443 - 463.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. L. King, S. J. Szilvassy, and A. Daugherty
Interleukin-4 deficiency promotes gallstone formation
J. Lipid Res.,
May 1, 2002;
43(5):
768 - 771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Davis, J. H. Miyake, T. Y. Hui, and N. J. Spann
Regulation of cholesterol-7{alpha}-hydroxylase: BAREly missing a SHP
J. Lipid Res.,
April 1, 2002;
43(4):
533 - 543.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Edwards, H. R. Kast, and A. M. Anisfeld
BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis
J. Lipid Res.,
January 1, 2002;
43(1):
2 - 12.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Miyake, X. T. Duong-Polk, J. M. Taylor, E. Z. Du, L. W. Castellani, A. J. Lusis, and R. A. Davis
Transgenic Expression of Cholesterol-7-{alpha}-Hydroxylase Prevents Atherosclerosis in C57BL/6J Mice
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2002;
22(1):
121 - 126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schwarz, D. L. Davis, B. R. Vick, and D. W. Russell
Genetic analysis of cholesterol accumulation in inbred mice
J. Lipid Res.,
November 1, 2001;
42(11):
1812 - 1819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gupta, R. T. Stravitz, P. Dent, and P. B. Hylemon
Down-regulation of Cholesterol 7alpha -Hydroxylase (CYP7A1) Gene Expression by Bile Acids in Primary Rat Hepatocytes Is Mediated by the c-Jun N-terminal Kinase Pathway
J. Biol. Chem.,
May 4, 2001;
276(19):
15816 - 15822.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Luo, C.-p. Liang, and A. R. Tall
The Orphan Nuclear Receptor LRH-1 Potentiates the Sterol-mediated Induction of the Human CETP Gene by Liver X Receptor
J. Biol. Chem.,
June 29, 2001;
276(27):
24767 - 24773.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Miyake, X.-D. T. Doung, W. Strauss, G. L. Moore, L. W. Castellani, L. K. Curtiss, J. M. Taylor, and R. A. Davis
Increased Production of Apolipoprotein B-containing Lipoproteins in the Absence of Hyperlipidemia in Transgenic Mice Expressing Cholesterol 7alpha -Hydroxylase
J. Biol. Chem.,
June 22, 2001;
276(26):
23304 - 23311.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. De Fabiani, N. Mitro, A. C. Anzulovich, A. Pinelli, G. Galli, and M. Crestani
The Negative Effects of Bile Acids and Tumor Necrosis Factor-alpha on the Transcription of Cholesterol 7alpha -Hydroxylase Gene (CYP7A1) Converge to Hepatic Nuclear Factor-4. A NOVEL MECHANISM OF FEEDBACK REGULATION OF BILE ACID SYNTHESIS MEDIATED BY NUCLEAR RECEPTORS
J. Biol. Chem.,
August 10, 2001;
276(33):
30708 - 30716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Zollner, P. Fickert, D. Silbert, A. Fuchsbichler, C. Stumptner, K. Zatloukal, H. Denk, and M. Trauner
Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice
Am J Physiol Gastrointest Liver Physiol,
January 1, 2002;
282(1):
G184 - G191.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|